Type 2 diabetes (T2D) and cancers are two major causes of morbidity and mortality worldwide. Nowadays, there is convincing evidence of positive associations between T2D and the incidence or prognosis of a wide spectrum of cancers, for example, breast, colon, liver and pancreas. Many observational studies suggest that certain medications used to treat hyperglycemia (or T2D) may affect cancer cells directly or indirectly. The potential mechanisms of the direct T2D cancer links have been hypothesized to be hyperinsulinemia, hyperglycemia and chronic inflammation; however, the metabolic pathways that lead to T2D and cancers still remain elusive. Plasma-free amino acid (PFAA) profiles have been highlighted in their associations with the risks of developing T2D and cancers in individuals with different ethnic groups and degree of obesity. The alterations of PFAAs might be predominately caused by the metabolic shift resulted from insulin resistance. The underlying mechanisms have not been fully elucidated, in particular whether the amino acids are contributing to these diseases development in a causal manner. This review addresses the molecular and clinical associations between PFAA alterations and both T2D and cancers, and interprets possible mechanisms involved. Revealing these interactions and mechanisms may improve our understanding of the complex pathogenesis of diabetes and cancers and improve their treatment strategies.
Diabetes mellitus (DM) and cancer are two severe chronic diseases with tremendous impact on global health. Epidemiologic studies have shown that several forms of cancers, such as liver, pancreas, endometrium, colorectal, breast and bladder, develop more frequently in patients with diabetes.1, 2 Diabetes (primarily type 2, T2D) and cancers share many common risk factors, for example, aging, physical inactivity, diet and obesity. The potential biologic links between these two diseases are yet incompletely understood but may involve insulin resistance.3
Insulin resistance, intertwined with hyperinsulinemia, has been suggested as one of the possible underlying mechanisms for the direct connection between T2D and cancers.3 T2D is typically preceded by hyperinsulinemia to maintain glucose homeostasis.4 Additionally, convincing evidence have suggested that hyperinsulinemia may affect the signaling pathways of insulin and insulin-like growth factor 1 (IGF-1) and thus facilitate cancer development and progression.5 The etiology of insulin resistance has been either focused on lipid-mediated mechanisms6 or the interplay with obesity, which induces metabolic abnormalities.7 The latter is partly reflected in the abnormal circulating levels of lipid, protein and other classes of metabolites. Among the numerous metabolites, amino acids may have potential as excellent disease biomarkers because they are involved in protein synthesis and as metabolic regulators.8 In 1969, hyperaminoacidemia, manifested by elevated plasma-free amino acids (PFAAs) including branched-chain amino acids (BCAAs), that is, valine (Val), leucine (Leu), isoleucine (Ile) and aromatic amino acids (AAAs), that is, tyrosine (Tyr) and phenylalanine (Phe) in obese subjects, was reported.9 Hyperaminoacidemia in obesity may be a manifestation of increased insulin resistance.
Insulin has long been recognized as the regulator of branched-chain alpha-keto acid dehydrogenase complex, an enzyme complex involved in BCAA catabolism.10 Insulin resistance has been found to reduce the enzymatic activity of branched-chain alpha-keto acid dehydrogenase complex and hence suppress BCAA catabolism. This is considered as the plausible etiology of increased BCAA levels in obesity and/or diabetes.11 Indeed, evidence is accumulating that there is positive association between insulin resistance and circulating concentrations of BCAAs.12, 13, 14, 15 In addition, insulin resistance was shown to be correlated with the alterations of several other PFAAs, including AAAs, alanine (Ala), proline (Pro) and glycine (Gly).16
In recent years, PFAA profiles were found to be significantly altered in patients with diabetes and/or cancers.17, 18, 19, 20, 21 Little is known about the mechanisms, particularly whether PFAAs are contributing to the development of these diseases in a causal manner. However, the altered PFAA profiling appears to provide a great diagnostic potential and could be a promising biomarker for understanding the etiology and pathogenesis of diabetes and cancers.22
Altered PFAA profiles in cancer patients
Cancer cells require certain amino acids, for example, glutamine (Gln), Gly, aspartic acid (Asp) and serine (Ser), for DNA synthesis, building new blood vessels, and duplicating their entire protein contents.23 They also require amino acids for proteins synthesis. These proteins work as growth-promoting hormones or tumor growth factors.24, 25 The increase in the amino acid demand may thus lead to a lower availability of PFAAs in cancer patients.26 Table 1 summarizes twenty studies specifically addressed the alterations of circulating amino acid concentrations in different cancer patients.
Vissers et al.27 analyzed the PFAA concentrations in three types of cancer patients with different levels of weight loss, that is, breast cancer (without weight loss), colonic cancer (occasional weight loss) and pancreatic cancer (frequent weight loss). They found a significant decrease in arginine (Arg) levels, regardless of tumor types and stages, weight loss or body mass index. This finding suggested that decreased Arg availability was a specific feature of the presence of a malignant tumor. They also revealed that BCAA concentrations were lower in all cancer patients than in age- and sex-matched controls; whereas TAAs were lower only in pancreatic cancer patients. It should be noted that the alterations of PFAA levels depend on the stage and the type of cancers. The study conducted by Gu et al.28 examined the PFAA profiles in 56 patients with gastric cancer, 28 patients with breast cancer, 33 patients with thyroid cancer and 137 healthy controls which were age matched. It was found that histidine (His) level was significantly decreased in breast cancer patients. Levels of Ser, Ala, Val, lysine (Lys), His, BCAAs, and TAAs were significantly decreased in gastric cancer patients. However, the thyroid cancer patients had significantly increased levels of methionine (Met), Leu, Tyr and Lys (Table 1). Besides the different types of cancers, the variation of PFAA pattern of patients was due to the different disease stages. Most of the patients with breast cancer or thyroid cancer in this study were characterized as early stage, whereas 12 of gastric cancer patients were characterized as advanced stage (stage IV). This study also showed that Ala, Arg, Asp and cysteine (Cys) promoted the proliferation of breast cancer cells. Alternatively, Cys promoted the proliferation of gastric cancer cells, but Ala and glutamic acid (Glu) inhibited it. These results underscored the potential function of the assessment of tumor-related PFAA patterns to examine and diagnose various cancers.
Recently, AminoIndex Cancer Screening (AICS) technology was employed as a novel cancer risk calculation method for early stage cancer diagnosis.21, 29, 30, 45, 46 In order to build AICS, 19 amino acids including threonine (Thr), asparagine (Asn), Ser, Gln, Pro, Gly, Ala, citrulline (Cit), Val, Met, Ile, Leu, Tyr, Phe, His, tryptophan (Trp), ornithine (Orn), Lys and Arg, were measured and statistically analyzed. For the colorectal cancer risk calculation in one case report,21 plasma levels of Ser, Pro, Val, Met, Ile and Lys were used. The AICS score was found to be 8.3, which indicated that the patient had an ~10-fold-increased risk of cancer. When the patient underwent colonscopy, a 10-mm adenoma-like lesion in the ascending colon with partial carcinoma was observed. The early detection of carcinoma using AICS method allowed complete resection, suggesting that PFAA profiles may provide a fast and easy diagnostic tool for cancers. Another study conducted by Fukutake et al.20 used Ser, Asp, Ile, Ala, His and Trp as variables to calculate the pancreatic cancer risk and successfully discriminate patients with pancreatic cancer (n=360) from control subjects (n=8372). They also analyzed the levels of 19 amino acids and a significant increase in Ser level and significant decreases in the levels of Thr, Asn, Pro, Ala, Cit, Val, Met, Leu, Tyr, Phe, His, Trp, Lys and Arg were observed in pancreatic cancer patients. Several other studies with small sample size37, 38 reported similar decreases in circulating amino acid levels in pancreatic cancer patients, which was interpreted as a result of the enhanced usage of PFAAs in tumors. Another possibility for the decreased levels of amino acids was associated with malnutrition. Patients with pancreatic cancer are usually troubled by malnutrition due to exocrine pancreatic insufficiency (EPI).
However, some studies investigating amino acid levels in plasma or serum samples from patients with breast cancer showed contradictory results (Table 1). Poschke et al.31 reported increased levels of Glu, Ser, Gln, Ala, Val, Phe, Ile and Leu in 41 breast cancer patients. One possible explanation could be that the stage of tumor in this study population was categorized as early stage such that it did not reduce the amino acid pool. The increased level of Ser was probably due to the increased enzymatic activity involved in Ser biosynthesis in tumor cells.47 The increased levels of Glu and Ala may be produced by tumor cells.48 Similar increment of amino acid levels, that is, Orn, Glu and Trp in breast cancer patients, was observed previously.49 However, other study demonstrated a decrease of Gln, Tyr, Phe, His and Trp, whereas an increase of Thr, Ser, Pro, Gly, Ala, Orn and Lys, in 196 patients with breast cancer.29 The above mentioned contradictory results might be attributed to the differences in participant characteristics, including age, gender, ethnic background, diet, and countries where participants live, different measurement techniques applied for PFAA profiles, different diseases stage, and lack of data adjustment for potential confounders. Meanwhile, PFAA profiles may be affected by various factors, including the amount and/or composition of dietary protein, metabolism of muscle protein, as well as the labile protein reserve in different tissues.
Mechanism underlying alterations of PFAA profiles
Table 1 shows that patients with cancers have altered PFAA profiles. Apparently, the pattern and degree of the alterations depend on the type of cancer and the disease stage. Determination of the precise mechanism underlying changes in the PFAA profiles has the great potential for cancer diagnosis and treatment. Various recent studies tried to find out the connections between cancers and specific PFAA profiles (Table 2). Among all of the amino acids, Gln has attracted great attentions as cancer cells are known to be avid consumers of Gln.50, 51 Building on the Warburg effect,52 cancer cells extensively use Gln to produce ATP (adenosine-triphosphate) to sustain anabolism, which is necessary for tumor growth and proliferation. It has been demonstrated that breast cancer cell lines expressing high levels of c-MYC were dependent on Gln for their survival and growth.53 As shown in Table 1, significant decrease of Gln was observed in patients with pancreatic cancer,27, 38 Lung cancer, gastric cancer, colorectal cancer, breast cancer and prostate cancer.29 On the other hand, the increased Glu levels in colorectal cancer patients30 and breast cancer patients30, 31, 32 could also be interpreted as the result of increased Gln metabolism in tumor cells. Although Gln consumption is increased in most tumors, some cancer cells can survive and proliferate by relying on glucose without Gln.54
Gly and Ser are biosynthetically linked, both of which are classic metabolites of glycolysis. The biosynthesis pathway of Ser utilizes the glycolysis intermediate 3-phosphoglycerate, which is converted by phosphoglycerate dehydrogenase, phosphoserine aminotransferase and phosphoserine phosphatise into Ser. In Gly metabolism, Gly is converted to methylenetetrahydrofolate by glycine decarboxylase. Meanwhile, serine hydroxymethyltransferase converts Ser to Gly reversibly, linking the respective pathways of metabolism. Jain et al.55 reported that Gly biosynthetic pathway was closely linked to cancer cell proliferation. A significant correlation between Gly consumption and cancer cell proliferation was observed, suggesting that Gly uptake and catabolism was able to promote tumourigenesis and malignancy. Additionally, emerging evidence suggested that aberrant activation of the biosynthetic pathway of Ser was an essential process in cancer pathogenesis.56 According to previous studies, glycine decarboxylase is highly expressed in several human cancers, including ovarian cancer,55 non-small-cell lung carcinoma57 and breast cancer.58 Phosphoglycerate dehydrogenase (the key enzyme for Ser biosynthesis) expression is normally upregulated in breast cancer and melanoma.59 As summarized in Table 1, Gly consumption was pronounced in pancreatic cancer,27 breast cancer,28, 29 colorectal cancer41 and cervical cancer.42 While Ser levels were high in some patients with pancreatic cancer,20 breast cancer,31, 32 lung cancer, and colorectal cancer,29 probably due to the overexpression of phosphoglycerate dehydrogenase, other cancers, such as colorectal cancer,21, 27, 42 pancreatic cancer,27 gastric cancer28 and cervical cancer43 consumed Ser. Although Ser and Gly could be inter-converted and either of them might be used for one-carbon metabolism and nucleotide synthesis, convincing evidence suggested that cancer cell proliferation were supported by Ser instead of Gly consumption. Gly was believed to be a consequence of the rapid cell proliferation.60
It is well-known that the BCAAs have important roles in the maintenance of lean body mass and regulation of skeletal muscle protein metabolism. Therefore, the investigation of BCAAs and their metabolites in the cancer-bearing state, where muscle wasting is a significant comorbidity, is of importance. Elevated plasma BCAAs levels have been observed to raise the risk of future diagnosis of pancreatic cancer by two-fold.61 The high BCAA concentrations were attributed to the enhanced whole-body protein breakdown in development of pancreatic ductal adenocarcinoma. Therefore, BCAA profiles could be used as a general marker to diagnose pancreatic ductal adenocarcinoma. In addition, the direct effects of BCAAs on cultured human hepatocellular carcinoma cells have also been reported previously.62 It was found that increased BCAAs levels suppressed the hepatocellular carcinoma cell lines proliferation. One of the plausible mechanisms underlying suppression of cancer cells by BCAAs was associated with their capability of inhibition of insulin signals through suppressing the expression of IGF.63 It is believed that insulin induced cell proliferation by activating the mitogen-activated protein kinase pathway.64 BCAAs have also been reported to accelerate mRNA degradation of insulin-induced vascular endothelial growth factor at the post transcriptional level, downregulating vascular endothelial growth factor expression during the hepatocellular carcinomas development.65 Furthermore, BCAAs were reported to induce the apoptosis of liver cancer cell lines by inhibiting insulin-induced phosphatidylinositol-3-kinase (PI3K)/Akt and the nuclear factor-kappa beta (NF-κB) signaling pathways through the mammalian target of rapamycin complex 1- (mTORC1) and complex 2- (mTORC2) dependent mechanisms.66
Some other amino acids, such as Tau, have been reported to decrease human cervical cancer cell proliferation in a dose- and time-dependent manner.67 It was also suggested that assessment of serum Tau levels in patients with high breast cancer risk was useful in the early diagnosis of malignant changes in breast.68 Additionally, plasma Arg levels were lower in patients with cancers, indicating that Arg metabolism may be disturbed in the presence of a malignancy.27, 44, 69 Although the metabolic changes of different cancers can determine their own unique PFAA profiles, the role of cancer-specific amino acids remains to be elucidated. Further studies are required to verify the significance of PFAA alterations in cancers development and management.
Altered PFAA profiles in diabetes mellitus
T2D is characterized by insulin resistance and/or impaired insulin secretion from beta cells. The prevalence of T2D is markedly increasing around the world and the rates of increase show no signs of slowing.70 A complete understanding of the pathophysiology of insulin resistance and T2D, or the identification of early stage metabolic alterations, is promising in the study of etiological pathways and may hold the potential to develop preventive strategies. A number of biomarkers, including fasting plasma glucose and glycated hemoglobinA1c, have been proposed as indicators for the estimation of T2D risk.71 Yet many populations from overweight to moderately obese have completely normal fasting plasma glucose and hemoglobinA1c, leaving them undiagnosed as pre-diabetics in spite of underlying dysfunctional metabolism. This highlights the fact that only considering glucose metabolism was not sufficient when determining the etiology and consequences of T2D.72
More and more metabolomics-based studies have consistently reported the perturbation of normal amino acid metabolism in insulin resistance and T2D in recent years.73 Multiple amino acids, particularly BCAAs, have been shown to be modulators of insulin secretion.74, 75 Increasing evidence suggests that elevated plasma BCAAs levels may have adverse effects on the regulation of glucose homeostasis, because the oxidation of BCAAs spares glucose utilization in skeletal muscle.76 On the other hand, for individuals without significant abnormalities in glucose homeostasis, elevations in BCAAs levels, along with AAAs are also significantly associated with an increased future likelihood of developing T2D77 and cardiovascular diseases.78 One of the possible mechanisms by which hyperaminoacidemia could promote DM is via hyperinsulinemia leading to pancreatic beta cell exhaustion. The association between insulin resistance and increased circulating BCAAs levels were supported by several other studies with different ethnic groups and degree of obesity.12, 13, 14, 16, 79, 80 Table 3 summarizes 16 recent studies reporting the associations between PFAA profiles and insulin resistance and T2D.
Shah et al.13 conducted a large randomized trial to understand health benefits occurring as a result of weight loss by using high-throughput metabolomic profiling. They found that BCAAs were unique to predict the improvement in HOMA-IR (homeostasis model assessment of insulin resistance), and suggested a potential mechanism for the heterogeneity in health benefits obtained from weight loss. The associations between BCAAs concentrations and adverse metabolic profiles were also observed in children and adolescents. It is noteworthy that the elevations in BCAAs may independently predict future insulin resistance in these participants.14 In the Framingham Offspring Study, BCAAs and AAAs were found to have significant relationships with future development of DM.77 The combination of three amino acids, that is, Ile, Phe and Tyr, predicted future DM with a four- to six-fold increased risk for participants in top quartile. The combination of Ile, Phe and Tyr also helped to predict future cardiovascular diseases during a long-term follow-up, probably through increased tendency towards the development of atherosclerosis.78 The plausible etiology of elevated BCAAs levels in obesity is through the suppression of BCAA catabolism by insulin resistance.11 It should be noted that, besides obesity-associated insulin resistance, BCAAs levels were also positively correlated with HOMA-IR in individuals with normal body mass.16, 80 The underlying mechanisms between insulin resistance and elevated BCAAs are related with the persistent activations of mTORC and S6K1 as shown in Table 4.
Increased circulating levels of Phe and Tyr (or AAAs) have been reported to be associated with insulin resistant, T2D or cardiovascular diseases states.77, 78, 79, 80, 82, 84, 87, 88 The directionality of the blood concentration shifts of Phe and Tyr are usually the same because Tyr is the first product of Phe catabolism. In the studies using blood metabolites to predict T2D77 and determining correlations between metabolites and insulin sensitivity,89 Phe and Tyr provided some of the strongest associations. The positive correlation between Phe and/or Tyr and insulin secretion may be involved in pathways to compensate early stage of insulin resistance through stimulating insulin secretion (Table 4).
Contrary to BCAAs and AAAs, the relationships of other amino acids with insulin resistance remain incompletely understood. Nakamura et al.81 recruited 51 of patients with T2D and measured their PFAA profiles. They observed that the levels of Glu, Ala, Trp and BCAAs were inversely correlated with adiponectin concentrations. As adiponectin is very important in the regulation of insulin sensitivity and metabolism, it might be the cause of insulin resistance and change PFAA profiles in diabetic patients. They also found that the concentrations of Ala, Tyr, Glu and Pro were significantly correlated with fasting plasma insulin. There results indicated the strong association between PFAA profiles, circulating adiponectin concentration and insulin resistance; however, the underlying mechanism was unclear. Some other studies in healthy obese82, 83 and in pre-diabetic subjects84 suggested that the levels of Ala, Gly, Gln, Glu, Trp, Tyr and BCAAs were correlated with visceral adiposity which was associated with deregulated insulin signaling. However, in the EPIC-Potsdam case–cohort,85 increased concentration of Phe and reduced concentration of Gly were found to be independently predictive of T2D. Unlike Phe which stimulated insulin secretion, the depletion of Gly may reflect increased gluconeogenesis or glutathione consumption driven by oxidative stress.90
Conclusions and future directions
This review has highlighted the potential use of the PFAA profiling as a novel diagnostic tool to access the risk of cancers and T2D. Results from epidemiological studies have suggested that obesity and T2D are positively correlated with the increased risk of several cancers. The underlying link between obesity, T2D, and cancer is related to insulin resistance, hyperinsulinemia, and disturbances in IGF signaling systems (Figure 1). The insulin resistant state is correlated with a metabolic profile of altered metabolism of protein, which may affect the PFAA profiles. Looking at previous clinical data, the metabolic alterations of insulin resistance, T2D or cancers can determine their own unique PFAA profiles. Although PFAA alterations can be used for diagnosis of cancers or T2D with sufficient sensitivity and robustness, the specificity is low. The discrepancies exist between the results of previous studies due to the variations in participant characteristics, for example, age, gender, ethnic background, degree of obesity, diet, different techniques for amino acids measurement, different types and stages of cancers and limited size of data set.
Future research is needed to investigate the characteristic PFAA profiles to discriminate individual cancer types with different stages from healthy controls. Additional validation of the profiles using a larger sample size is necessary to establish the clinical utility. Furthermore, it is needed to elucidate the biological mechanisms by which amino acids might promote cancer risk and progression or T2D and its complications because the roles of insulin resistance or hyperinsulinemia or hyperglycemia in regulating the enzymes utilizing amino acids are still incompletely understood. Although our understanding of alterations in PFAAs metabolism in the diabetic or cancer states remains immature, we believe that PFAA profiling has the clinical usefulness for the detection of cancers or T2D.
On the other hand, while it is evident that Asian populations are more insulin resistant than other ethnic groups, in spite of less obesity, it is necessary to better identify the factors underlying the interethnic differences. As mentioned earlier, PFAA profiles have been utilized as biomarkers to detect cancers and diabetes. However, few studies have been investigated whether specific populations in Asia may have different PFAA profiles. To our best knowledge, only a few studies have been conducted in Asian populations, most of which are limited to Japanese. The rising prevalence of diabetes and cancers in Asia urgently need to clarify the associations of PFAA profiles with these diseases. These findings may provide new insight into how dietary or other interventions alter PFAA profiling in humans and to access whether these changes could ultimately improve metabolic health in cancer patients or pre-diabetes or T2D patients.
The authors greatly acknowledge the financial support from Singapore Institute for Clinical Sciences, Agency for Science, Technology, and Research (A*Star), Singapore.
About this article
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/